Protective antigen · SINGLE PROTEIN · Bacillus anthracis
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Protective antigen shows approved-linked disease relevance led by anthrax infection. 1 more disease program remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P13423. Start with anthrax infection, then reuse UniProt P13423 as the stable protein anchor across project notes and exports.
Start with anthrax infection, then reuse UniProt P13423 as the stable protein anchor across project notes and exports.
Protective antigen shows approved-linked disease relevance led by anthrax infection. 1 more disease program remain visible in the same review block. 5 linked drugs remain visible in the same block.
Start review with anthrax infection because it currently carries approved-linked support. Linked drugs include AVP-21D9, BACILLUS ANTHRACIS PROTECTIVE ANTIGEN, ADSORBED, MDX-1303, OBILTOXAXIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyProtective antigen
Review this target as Protective antigen, mapped to UniProt P13423. Sequence length is 764 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Protective antigen as ChEMBL target CHEMBL5352, mapped to UniProt P13423. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Protective antigen is the right protein anchor across sources, using UniProt P13423 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why anthrax infection is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Protective antigen |
| Target Type | SINGLE PROTEIN |
| Organism | Bacillus anthracis |
| UniProt | P13423 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Protective antigen |
| UniProt Accession | P13423 |
| Component Type | Protein |
| Sequence Length | 764 aa |
Protective antigen
Review this target as Protective antigen, mapped to UniProt P13423. Sequence length is 764 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Protective antigen shows approved-linked disease relevance led by anthrax infection. 1 more disease program remain visible in the same review block.
Start review with anthrax infection because it currently carries approved-linked support. Linked drugs include AVP-21D9, BACILLUS ANTHRACIS PROTECTIVE ANTIGEN, ADSORBED, MDX-1303, OBILTOXAXIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL2179141 | 6.0 | EC50 | 1000.0 | Preclinical |
| CHEMBL2179142 | 6.0 | EC50 | 1000.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 29 | 2 | 5.9 |
| assay format | 1 | 0 | — |
| single protein format | 1 | 0 | — |